CN101977589B - Chitosan gel for dermatological use, production method therefor and use of same - Google Patents

Chitosan gel for dermatological use, production method therefor and use of same Download PDF

Info

Publication number
CN101977589B
CN101977589B CN200980109724.7A CN200980109724A CN101977589B CN 101977589 B CN101977589 B CN 101977589B CN 200980109724 A CN200980109724 A CN 200980109724A CN 101977589 B CN101977589 B CN 101977589B
Authority
CN
China
Prior art keywords
acid
gel
chitosan
skin
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980109724.7A
Other languages
Chinese (zh)
Other versions
CN101977589A (en
Inventor
阿里尔·沙乌尔哈森尼西斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Igloo Zone Chile SL
Gynopharm SA
Original Assignee
Igloo Zone Chile SL
Gynopharm SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igloo Zone Chile SL, Gynopharm SA filed Critical Igloo Zone Chile SL
Publication of CN101977589A publication Critical patent/CN101977589A/en
Application granted granted Critical
Publication of CN101977589B publication Critical patent/CN101977589B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to pharmaceutical compositions designed to leave a protective film on the skin, comprising chitosan and agents conferring curative, calming and hydrating properties on irritated skin. The gel is characterised in that it includes between 2 and 8 % chitosan and pre-defined proportions of other components such as between 0.1 and 90 % Portulaca and between 0.1 and 45 % Panthenol, which confer improved therapeutic characteristics on the product, and other components which provide the gel with particular characteristics and render same suitably stable over a prolonged period of time. Said gel is applied externally and is suitable for use on irritated skin, superficial burns, dermabrasions, post-dermabrasion, post-laser treatment and on eroded skin in general.

Description

Chitosan gel rubber, Its Preparation Method And Use that dermatological is used
Invention is described
The present invention relates to the gel based on chitosan, and relate more specifically to the gel that the excipient preparation of protectiveness thin film is provided after application on skin.
The present invention relates to be characterized as and mix chitosan as the topical application gel of main component.
Chitosan, from natural origin, is therefore biocompatible.It also demonstrates the intrinsic antimicrobial property of its internal characteristics (antifungal and bactericide).It is corresponding to the deacetylated straight-chain polysaccharide of N-acetyl group-GLUCOSAMINE of the deacetylated commercial acquisition of chitin.
Chitosan absorbs for the heavy metal of water and Industry Waste logistics (industrial waste flow), and for developing cosmetic preparation.In addition, the chitin of partial acetylation and chitosan derivatives have been the themes of finding the important research of therapeutant or implantable material.The biocompatibility of the material that comprises chitosan is evaluated specially on blood, wound and bone.
Chitosan (Cohya Y.Cois (1993) J.Microencapsulation, 10 (1): 1-9) in the drug delivery system by gel, have been studied.
In order to carry out the present invention, use many mixture to obtain solution, this solution provides the gel preparation of the percentage ratio of chitosan between 2% to 8%, be associated with other components that suitable treatment characteristic is provided to product, and be applied to after allergic skin, scorch, skin abrasion, desquamation, after laser and cover substantially corrosivity skin.
Chitosan (poly--β-Isosorbide-5-Nitrae-GLUCOSAMINE) is the natural polysaccharide derivant that is called chitin (poly--β-Isosorbide-5-Nitrae-D-acetylglucosamine), and described chitin is mainly found in shell-fish ectoskeleton.
By adding some materials (chitosan, Herba Portulacae, alpha-hydroxy acid, panthenol and harmless antiseptic), can improve and improve the character of biodegradable polymer.By using the biological degradability of acceptance and the composition of therapeutic properties with general at burn in the skin of damaged or corrosion, the support gel of the present invention of generation is fully biodegradable, has the character of improvement, and they can low cost obtain.
The main Types in water by chitosan is dissolved in good solubility is the organic acid soln of 'alpha '-hydroxy acids, obtain chitosan gel rubber, described alpha-hydroxy acid such as glycolic, lactic acid, α hydroxyacetic acid, α Hydroxycaprylic acid (alpha hydroxyoctanoic acid), α hydroxyl caprylic acid (alphahydroxycaprilic acid), malic acid, citric acid and tartaric acid.By using 25,000g/mol to 1, the number molecular weight scope between 250,000g/mol the chitosan having higher than 80% de-acetyl level obtain hydrogel.
In order to improve the character of hydrogel, add another natural materials of panthenol and Herba Portulacae and similar characteristic, the ratio of every kind changes between 0.1% to 45%.
Unexpectedly obtained the stable article of pH 5.0 to 5.9, its chitosan with the percentage ratio between 0.2% to 10% is prepared as unique viscosifier (viscosifier), by adding at least two kinds of antiseptic, also comprise Herba Portulacae and panthenol and another natural component, described another natural component provides the correlated characteristic of the type damage for the treatment of burn or skin corrosion, causes rapid regeneration and the healing of damaged tissues.
In a series of additional photos, pay close attention to the effect of hydrogel to damaged skin.Caption is as follows:
Fig. 1 shows the lower limb of the people with scorch
Leg area after Fig. 2 and 3 display application hydrogels, it has one deck tissue protective and reproducibility product.
Fig. 4 shows the region of product application after three days, has the treatment benefit that obvious damaged tissues recovers to have proved hydrogel.
Method prepared by hydrogel is as follows:
In thering is the rustless steel container of distilled water, add the organic acid of dilution, by its homogenize, and during preparing hydrogel, make pH remain between 4.0 to 4.5; Then, all chitosans that comprise in formula are slowly added until dissolve completely under continuous stirring.
Then, add polyaminopropyl biguanide, gluconic acid lactone, sodium benzoate and calcium gluconate antiseptic, or the mixture of other antiseptic of comprising of this patent, then add Herba Portulacae or another natural extract, then add panthenol.
Finally, between pH regulator to 5.0 and 5.9, use organic acid soln or 2% sodium hydroxide solution of the dilution between 1% and 2% for this reason.
Then goods are stored in hermetic container, until subpackage (fractioning).
In this patent, the compositions of report is exemplary, but does not limit the scope of the invention and protect.
Embodiment 1
Chitosan powder 3.50g
Polyaminopropyl biguanide 1.50g
Herba portulacae extract 4.00g
Panthenol 4.00g
The appropriate pH 5.5 of citric acid 1%w/v
Distilled water, appropriate 100g
Embodiment 2
Chitosan powder 4.00g
Polyaminopropyl biguanide 1.5g
Herba portulacae extract 6.0g
Panthenol 4.0g
The appropriate pH 5.5 of citric acid 1%p/v
Distilled water, appropriate 100g
Embodiment 3
Chitosan powder 4.00g
Polyaminopropyl biguanide 1.5g
Herba portulacae extract 4.0g
Panthenol 6.0g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
Embodiment 4
Chitosan powder 8.0g
Polyaminopropyl biguanide 1.5g
Herba portulacae extract 4.0g
Panthenol 6.0g
The appropriate pH 5.5 of citric acid 1%p/v
Distilled water, appropriate 100g
Embodiment 5
Chitosan powder 3.50g
Polyaminopropyl biguanide 1.50g
Gluconic acid lactone/sodium benzoate/calcium gluconate 1.50g
Herba portulacae extract 4.00g
Panthenol 4.00g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
Embodiment 6
Chitosan powder 4.0g
Polyaminopropyl biguanide 1.50g
Gluconic acid lactone/sodium benzoate/calcium gluconate 1.50g
Herba portulacae extract 6.00g
Panthenol 4.00g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
Embodiment 7
Chitosan powder 4.0g
Polyaminopropyl biguanide 1.50g
Gluconic acid lactone/sodium benzoate/calcium gluconate 1.50g
Herba portulacae extract 4.00g
Panthenol 6.00g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
Embodiment 8
Chitosan powder 8.0g
Polyaminopropyl biguanide 1.50g
Gluconic acid lactone/sodium benzoate/calcium gluconate 1.50g
Herba portulacae extract 4.00g
Panthenol 6.00g
The appropriate pH 5.5 of lactic acid 1%p/v
Distilled water, appropriate 100g
The stability of compositions
1st month 2nd month 3rd month
Embodiment Viscosity pH Microbiology Viscosity pH Microbiology Viscosity pH Microbiology
1 10,000cps 5.5 Lower than 100 100cps 5.4 Higher than 1000 100cps 5.4 Higher than 1000
2 12,000cps 5.5 Lower than 100 50cps 5.5 Higher than 1000 50cps 5.5 Higher than 1000
3 12,000cps 5.5 Lower than 100 200cps 5.4 Higher than 1000 200cps 5.2 Higher than 1000
4 15,000cps 5.5 Lower than 100 200cps 5.3 Higher than 1000 200cps 5.3 Higher than 1000
5 11,000cps 5.5 Lower than 100 11,500cps 55 Lower than 100 11,900cps 5.5 Lower than 100
6 14,000cps 5.5 Lower than 100 14,800cps 5.4 Lower than 100 14,600cps 5.4 Lower than 100
7 15,000cps 5.5 Lower than 100 15,300cps 5.4 Lower than 100 15,100cps 5.5 Lower than 100
8 18,000cps 5.5 Lower than 100 18,200cps 5.5 Lower than 100 18,100cps 5.5 Lower than 100
The explanation of end product:
Outward appearance, in midium-viscosity gel, suspension without external source granule, yellowish and translucent color.K value is between 5.000cps and 20.000cps.
PH value is between 5.0 to 5.9
Microbiology: pathogen-free domestic and have a liking for warm aerobe≤100UFC/ gram, and fungus and yeast≤100UFC/g;
Table 1 shows the importance that comprises antiseptic in hydrogel blend composition, in embodiment 1 to 4, compositions has less variation, but the most important thing is only to comprise a kind of antiseptic, in embodiment 5 to 8, compositions has less variation, but the most important thing is the mixture that comprises antiseptic in their composition.From the result of table, observe: at the second month of research, notice that significant viscosity changes, observe to produce in preparation 1 to 4 and significantly reduce and significantly microbial contamination, particularly by fungal contamination.This does not occur in comprising the embodiment 5 to 8 of preservative blends.
Under the environmental condition (25 ℃ ± 2 ℃ and 60 ± 5%H) of normal temperature and relative humidity, carry out this measuring.
Need to use the mixture of antiseptic is unusual and beat all (product description) to keep this condition, because expected that a kind of use of antiseptic is enough to keep the stability of product.Only a kind of use of antiseptic will can not predicted the variation of those viscositys of observing.
Prior art
Many gels are disclosed for scorch treatment and allergic skin.
Hydrogel generally has high biocompatibility, and they are for medical science transplanting, treatment of wounds and are also used as the good candidate that medicine is controlled release and sustained release array.
Tomihata has studied in body and the degraded (K.Tomihata and Y.Ikada, Biomaterials 18,567-575 (1997)) of external chitin and chitosan.According to the hydrolysis rate of lysozyme, measure external degradation, and in Animal Experimental Study, measure vivo degradation.
Result shows that 100% acetylizad chitin and 69% deacetylated chitosan are degraded rapidly.
Disclose many hydrogels and be used for the treatment of wound and burn, the gel being formed by chitosan, G & W forms protectiveness film when being applied to skin, uses the chitosan concentration of 1-4%, preferably 1% concentration.This gel is proposed as pharmaceutical carrier substantially, such as silver sulfadiazine vasodilation, analgesic and anti-inflammatory agent (US 4,659,700).
Other hydrogels can have undissolved feature, because added the excipient (US 5,620,706) with opposite charges.
Hydrogel comprises polycation or the polynary medicine of similar chitosan, such as natural polycation, its with such as the polyanion complexation of xanthan gum.It is conventionally by sealing for controlled release preparation.
Other disclosed hydrogels are from the interaction of chitosan and polyvidon, their (N-vinyl lactam)-chitosan gel rubbers that is poly-, and absorb more in particular gel, and they can adhere to skin, have pliability, and are applicable to moulding.According to other preparation compositions, this gel can be used as wound, burn, beauty mask coating (cosmetic mask coating) and beauty treatment porcelain glaze coating (cosmetic enamel coating) (ES 211782).
Also disclose also other gels based on chitosan and polyvidon, comprised the chitosan of the neutralization and do not have with plasticizer and the mixture of poly-(n-vinyl lactam).Gel can form in wound or dressing packing, and wherein hydrocolloid can absorb exudate, and loss structure not.It also can be used as the pharmaceutical carrier (W02002/02079) of transdermal device.
For other of the part of prior art chitosan between chitosan-based in 0.1% to 0.5%, polynary alkoxide or sugar between 1% to 2%.The salt of mentioning can be glycerol binary monophosphate (glycerol dibasic monophosphate).
This gel can original position form, and parenteral administration, or can also be as the vehicle (ES 2205471) of using non-drug products.
Other chitosan preparations of describing in gel comprise uses chitosan or its salt, PAPE or sugar phosphate, plasticizer and therapeutic agent.It refers to aqueous solution or water slurry, and wherein plasticizer is triethyl citrate.The chitosan using has 40% or higher deacetylation.
This gel is for passing through the drug delivery across mucosa (mucose), and application is nose application, vaginal application, rectum application, oral application or ophthalmic applications (WO 2005/079749).
The gel that is used for the treatment of burn has also been described, the collagen protein of this gel based on partial hydrolysis, and add galactose, pectin and hydroxyethyl-cellulose monomer, this gel is used for the treatment of first-degree burn and second degree burns (US2003/000830).
For other disclosed gels of the part of prior art are formed by hydrophilic poly-(aldehyde) and the mixture of polymer, the choosing of described polymer is the following group forming freely: poly-(amide), poly-(amine), poly-(alcohol) and their mixture, comprise natural polymer, chitosan and belong to the mixture (WO00/47149) of poly-(amine).
This gel is substantially as active agent carrier or mixture, also as wound gauze.
The gel that is used for the treatment of burn is also disclosed, the polymer of this gel based on not comprising chitosan, by polyvinyl alcohol, agar and one or more natural polymers, prepared described natural polymer such as gelatin, chondrus ocellatus Holmes polysaccharide (carragenan), sodium alginate, carboxymethyl cellulose, guar gum and Radix Acaciae senegalis (WO01/30407).
Also disclose other hydrogels based on chitosan, it is preferably as antiseptic.This is the chitosan iodide (US2002/0119205) that by concentration range prepared by the chitosan between 5% to 25%, propylene glycol, ethylene glycol etc. and the elemental iodine of concentration range between 0.05% and 1%.
The skin of human body is on average a little more than 1.9m 2, in many functions of skin, except as disease barrier and allow to remove refuse and bodily protection, skin is extremely important for thermoregulation.When skin is destroyed or damages by any wound, traumatic skin impact not only causes somatic damage, also destroys the physiologic function of interior tissue.
Skin treating can or be also referred to as porosu solid through irrigating solution and coating sponge.
Be similar to chitosan, chitin analyzed as being with skin in the glycosaminoglycan found feature class seemingly, because chitin repetitive n-acetylglucosamine is present in hyaluronic acid, and be responsible for being formed on the protein fibre network of combination during wound healing.Therefore, chitin compound is also considered as promoter and the wound healing process reinforcing agent of skin rapid regeneration by several researcheres, because the healing rate that chitin shows makes it be used as the composition product of the medicine being applied on wound.
Because compare with chitin n-acetylglucosamine, the effect that the healing of the glycosamine residue in chitosan strengthens ability is lower, so chitosan is after the chitin as agglutination reinforcing agent.
Chitin is distributed widely in occurring in nature, is distributed in regnum animale and plant kingdom.In fact, it is the natural polymer more than second, only have cellulose to surpass it, so it is Renewable resource.This polymer comprises the amino sugar by β (1 4) glycosidic bond bonding, wherein forms N-acetyl group-2-amino-2-deoxy-D-Glucose unit straight chain, and some in them are by deacetylation.Natural chitin is proved to be the degree of acetylation with 66%, and every three unit just have one to be deacetylated.
Chitosan is the linear polysaccharide by chitin deacetylated acquisition on a large scale; and comprise construction unit N-acetyl group-GLUCOSAMINE and the GLUCOSAMINE along chain random distribution (Bemoullian distribution) of two types, between them, by β (1 4) type glycosidic bond, connect.Deacetylated chitosan structure is presented in Fig. 1 .2 completely.Yet it is very difficult making the completely de-acetyl of chitin, and what be commonly referred to chitosan is the chitin family having generally higher than 45% different degree of deacetylation.It is it and chitinous common acceptable standard of difference that chitosan is dissolved in ability in the aqueous acid of dilution.
Fig. 1 .2
All biomaterials for clinical setting should have excellent surface nature, because when this material implants, they directly contact living tissue.Initial somatic reaction to biomaterial depends on these character.
Chitosan can be used as artificial skin with healing acceleration, and for ulcer healing, or as the vehicle of drug release.The chitosan of positively charged and their biocompatibility provide effective Growth of Cells support.
Except providing to gel preparation the natural copolymer chitosan of special nature, also comprise other compositions, make product on allergic skin, burn and superficial cut, there is better effect.
Be a panthenol, also referred to as B5 provitamin, D-panthenol is converted to vitamin B5 in vivo, a kind of normal skin and hair composition, and its topical application is accelerated cell regeneration, and is powerful humidizer.
When the pantothenylol of topical application is converted into the D-VB5 (or simply pantothenic acid) of healthy skin, act on mitochondrial biochemical power generation circulation, and for lipid, protein synthesis and lipid-protein, to be connected with chain between saccharide be essential.
When enough d-pantothenic acid does not exist, produce known cutaneous manifestations, such as keratinization, depigmentation with come off.
Panthenol absorbs fast by skin, becomes pantothenic acid.
Cell regeneration is accelerated by the topical application of d-panthenol, because it has height skin penetrating power and special humidizer ability.It also contributes to the skin that humidification is aging, and be applied to ideally mild skin and stimulate (Lawrence Sweetman, Encyclopedia of Dietary Supplements (food additives encyclopedia), Pantothenic Acid (pantothenic acid), in February, 2005).
The compatible material of other biological can add in this chitosan gel rubber, and this material demonstrates advantage during local application in corrosion skin treating.One of this class material is Herba Portulacae, and it is available from the plant extract that is called Herba Portulacae.This extract has good irritation and antiinflammatory action when local use.Herba portulacae extract has been successfully used to several dermatopathies, such as eczema and abscess (the people .Las plantas silvestres.Los remedies hist ó ricosdermatol ó gicos.Med.Cutan.Iber.Lat.2003 such as PedroS á nchex Sambucety, 31 (5): 337-346).Having other native compounds of curing character and being used because of their skin treating character is extract and the linoleic acid from Olibanum wood (Boswellia sacra), Herba stellariae mediae, Big Semen Plantaginis, Flos Inulae, Boswellia carterii (Boswella carterii), Myrrha, Chamaemelum nobile (L.) A L L, Pelargonium gravelens.

Claims (10)

1. the hydrophilic stable gel based on topical application polymer, is characterized in that:
A) comprise chitosan,
B) chitosan is by adding dissolution with solvents,
C) comprise one or more materials that increase organized renewing ability,
D) comprise at least two kinds of antiseptic harmless to skin, described at least two kinds to the harmless antiseptic of skin, the mixture with polyaminopropyl biguanide, gluconic acid lactone, sodium benzoate and calcium gluconate exists, and the concentration of every kind of antiseptic changes between 0.1% to 30%.
2. gel according to claim 1, is characterized in that chitosan has 25,000g/mol to 1, and the molecular weight between 250,000g/mol, it is main hydrogel component, and exists with the ratio changing between 2% to 8%.
3. according to the gel described in any one in claim 1 to 2, it is characterized in that described solvent is from the organic acid that is selected from the dilution of following alpha-hydroxy acid family: glycolic, lactic acid, α hydroxyacetic acid, α Hydroxycaprylic acid, α hydroxyl caprylic acid, malic acid, citric acid and tartaric acid.
4. according to the gel described in any one in claim 1 to 2, it is characterized in that one or more materials of described increase organized renewing ability are selected from Herba portulacae extract, Herba stellariae mediae extract, Big Semen Plantaginis extract, Flos Inulae extract, Boswellia carterii extract, Myrrha extract, chamomile extract, Pelargonium gravelens extract and linoleic acid.
5. gel according to claim 4, it is characterized in that described increase organized renewing ability one or more materials each with percentage change between 0.1% to 45%, be included.
6. for obtaining a method for the gel of the topical application described in claim 1 to 5 any one, it is characterized in that thering are following steps:
A) by the 1-2%w/v weak organic acid solution that contains the chitosan between 2% to 8%w/w, prepare chitosan solution,
B) with the ratio changing between 0.1% to 30%, every kind of antiseptic is joined in the solution obtaining in (a),
C) then, after described this solution is even, under continuous stirring, with the ratio changing, add one or more materials that increase organized renewing ability between 0.1% to 45%,
D) finally use dilution organic acid soln between 2% sodium hydroxide solution or 1% to 2% by pH regulator to 5.0 between 5.9.
7. method according to claim 6, is characterized in that using being selected from following alpha-hydroxy acid as organic acid: glycolic, lactic acid, α hydroxyacetic acid, α Hydroxycaprylic acid, α hydroxyl caprylic acid, malic acid, citric acid and tartaric acid.
8. the purposes in the medicine for the preparation for the treatment of allergic skin and burn according to the gel described in any one in claim 1 to 5, is characterized in that described medicine is that topical application by thin layer is used for the treatment of allergic skin and burn.
9. the purposes in the medicine of the treatment after for the preparation for the treatment of skin abrasion, desquamation and after laser according to the gel described in any one in claim 1 to 5, it is characterized in that described medicine is by infected lip-deep applied in very thin layers, for the treatment after skin abrasion, desquamation and after laser.
10. the purposes in the medicine of the skin for the preparation for the treatment of corrosion according to the gel described in any one in claim 1 to 5, is characterized in that described medicine is by the application of the lip-deep layer being treated, and is used for the treatment of the skin of corrosion.
CN200980109724.7A 2008-01-18 2009-01-21 Chitosan gel for dermatological use, production method therefor and use of same Expired - Fee Related CN101977589B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL200800156A CL2008000156A1 (en) 2008-01-18 2008-01-18 STABLE HYDROPHYLE GEL BASED ON A POLYMER FOR TOPICAL APPLICATION BECAUSE IT INCLUDES DISSOLVED CHITOSANE IN A SOLVENT; PROCESS TO OBTAIN THE GEL FOR TOPICAL USE BEFORE MENTIONED; USE OF THE GEL.
PCT/IB2009/050228 WO2009090624A2 (en) 2008-01-18 2009-01-21 Chitosan gel for dermatological use, production method therefor and use of same

Publications (2)

Publication Number Publication Date
CN101977589A CN101977589A (en) 2011-02-16
CN101977589B true CN101977589B (en) 2014-12-10

Family

ID=40261146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980109724.7A Expired - Fee Related CN101977589B (en) 2008-01-18 2009-01-21 Chitosan gel for dermatological use, production method therefor and use of same

Country Status (14)

Country Link
US (1) US20100316739A1 (en)
EP (1) EP2452673B1 (en)
JP (1) JP5615717B2 (en)
CN (1) CN101977589B (en)
AR (1) AR071334A1 (en)
BR (1) BRPI0906932A2 (en)
CA (1) CA2712527C (en)
CL (1) CL2008000156A1 (en)
CO (1) CO6331421A2 (en)
EC (1) ECSP10010352A (en)
ES (1) ES2361459B1 (en)
MX (1) MX2010007902A (en)
PE (1) PE20091363A1 (en)
WO (1) WO2009090624A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055582A (en) * 2015-08-18 2015-11-18 云南同方科技有限公司 Formula essential oil for slight skin burns and scalds

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177825A1 (en) * 2011-06-21 2012-12-27 Bvw Holding Ag Medical device comprising boswellic acid
WO2013112381A2 (en) * 2012-01-24 2013-08-01 Bvw Holding Ag New class of anti-adhesion hydrogels with healing aspects
RU2526183C1 (en) * 2013-02-28 2014-08-20 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства (ФГУП НПЦ "Фармзащита" ФМБА России) Haemostatic anti-burn wound-healing composition
EP3119404B1 (en) * 2014-03-17 2019-07-24 Global Bioprotect IP Pty Ltd Antimicrobial sanitizer compositions and their use
CN103919689A (en) * 2014-03-20 2014-07-16 金红叶纸业集团有限公司 Wet tissue emulsion, wet tissue and preparation method of wet tissue
GB201501333D0 (en) 2015-01-27 2015-03-11 Medtrade Products Ltd Composition for a wound dressing
GB201501330D0 (en) * 2015-01-27 2015-03-11 Medtrade Products Ltd Composition for a wound dressing
EA026104B1 (en) * 2015-04-02 2017-03-31 Общество С Ограниченной Ответственностью "Тектум" Haemostatic and wound healing medicine
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US10660945B2 (en) 2015-08-07 2020-05-26 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
WO2018005145A1 (en) * 2016-06-28 2018-01-04 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US11058712B2 (en) 2017-07-19 2021-07-13 Universidade Da Beira Interior Film for topical application in the treatment of skin lesions and method of obtaining and applying same
CN108514546B (en) * 2018-05-14 2020-09-29 山东师范大学 Chitosan hydrogel preparation of dihydromyricetin and preparation method thereof
CN109731021A (en) * 2019-03-20 2019-05-10 武汉市思泰利医疗器械发展有限公司 It is a kind of for treat repair stoma skin aquagel and preparation method thereof
US20220211606A1 (en) * 2019-04-08 2022-07-07 Medoderm Gmbh Liquid composition for influencing the microbiota on a subject's skin comprising chitosan
EP3996914A4 (en) * 2019-07-11 2023-08-02 Stenco, LLC Biodegradable material
CN111920742A (en) * 2020-09-18 2020-11-13 微著生物科技(东营)有限责任公司 Chitosan multi-effect repair mask and preparation method thereof
EP4228595A1 (en) * 2020-10-14 2023-08-23 Medoderm GmbH Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease
DE102021109834A1 (en) * 2021-04-19 2022-10-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Composition for disinfection and cosmetic use
WO2023233299A1 (en) 2022-05-31 2023-12-07 Instituto Politécnico Da Guarda Wound dressing comprising a ph sensor composition and method of producing the same
WO2024136811A1 (en) * 2022-12-20 2024-06-27 Istanbul Medipol Universitesi Wound healing gel formulation comprising melaleuca viridiflora l. and boswellia carterii l.
US11845859B1 (en) 2023-03-28 2023-12-19 King Faisal University Biopolymer derived from algae

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659700A (en) 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material
US5142010A (en) * 1990-05-10 1992-08-25 H. B. Fuller Licensing & Financing Inc. Polymeric biocidal agents
AU9115791A (en) * 1990-11-30 1992-06-25 Baker Cummins Dermatologicals, Inc. Skin protective compositions and method of inhibiting skin irritation
US5420197A (en) 1994-01-13 1995-05-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
US5620706A (en) 1995-04-10 1997-04-15 Universite De Sherbrooke Polyionic insoluble hydrogels comprising xanthan and chitosan
SE507028C2 (en) * 1996-08-06 1998-03-16 Medicarb Ab New medical use
DE19719856A1 (en) * 1997-05-12 1998-11-19 Henkel Kgaa Skin care products
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
DE19826503A1 (en) * 1998-06-13 1999-12-16 Beiersdorf Ag Cosmetic and dermatological preparations containing chitosan and phospholipids
US6121375A (en) 1999-02-11 2000-09-19 Hydromer, Inc. Gels formed by the interaction of poly(aldehyde) with various substances
EP1223986A2 (en) * 1999-06-11 2002-07-24 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol)
WO2001030407A1 (en) 1999-10-27 2001-05-03 Department Of Atomic Energy A process for manufacture of hydrogels for burn and injury treatment
DE10010199A1 (en) * 2000-03-02 2001-09-06 Beiersdorf Ag Aqueous-alcoholic preparations containing chitosan
US6379702B1 (en) 2000-07-05 2002-04-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
KR100391781B1 (en) * 2000-12-14 2003-07-16 주식회사 제닉 Soft gel comprising chitosan and gelatin
US6521243B2 (en) 2000-12-22 2003-02-18 Pharma C And D, Limited Ionic chitosan -iodine complexes: antiseptic hydrogels and wound healing promoters
US20030000830A1 (en) 2001-02-23 2003-01-02 Techquip International, Inc. Stacked panel processing apparatus and methods
JP3947391B2 (en) * 2001-11-28 2007-07-18 独立行政法人 日本原子力研究開発機構 Method for producing chitin derivative and / or chitosan derivative having bridge structure
FR2836044A1 (en) * 2002-02-15 2003-08-22 Octaris COMPOSITION FOR REPAIR AND SKIN HEALING EXCLUSIVELY INCLUDING A TRUE PHYSICAL HYDROGEL OF CHITOSAN
EP2340856B2 (en) * 2003-05-24 2017-11-15 La Prairie Group AG Cosmetic or dermatologic formulation comprising a nutrient medium phase
KR100506543B1 (en) * 2003-08-14 2005-08-05 주식회사 제닉 Temperature Sensitive State-Changing Hydrogel Composition and Method for their Preparation
JP2006045181A (en) * 2003-11-18 2006-02-16 Sekisui Chem Co Ltd External composition for skin
GB0403938D0 (en) 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
US20050196450A1 (en) * 2004-03-04 2005-09-08 Elka Touitou Method and composition for burned skin
KR100676937B1 (en) * 2005-06-01 2007-02-02 주식회사 제닉 Water soluble film for skin care and wound repair and method for their preparation
US20070048358A1 (en) * 2005-08-31 2007-03-01 Schorr Phillip A Antimicrobial substrates
US20070237811A1 (en) * 2006-04-10 2007-10-11 Scherr George H Chitosan wound dressing
CN101057953A (en) * 2006-04-21 2007-10-24 陈祖辉 Multi-target cooperative control preparation for treating virus infectious disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055582A (en) * 2015-08-18 2015-11-18 云南同方科技有限公司 Formula essential oil for slight skin burns and scalds
CN105055582B (en) * 2015-08-18 2018-09-04 云南同方科技有限公司 A kind of formula essential oil for the slight burn and scald of skin

Also Published As

Publication number Publication date
JP5615717B2 (en) 2014-10-29
US20100316739A1 (en) 2010-12-16
WO2009090624A2 (en) 2009-07-23
EP2452673A4 (en) 2013-04-03
EP2452673B1 (en) 2017-04-26
BRPI0906932A2 (en) 2015-07-28
CO6331421A2 (en) 2011-10-20
WO2009090624A3 (en) 2009-09-11
EP2452673A2 (en) 2012-05-16
AR071334A1 (en) 2010-06-16
JP2012515710A (en) 2012-07-12
CA2712527C (en) 2017-02-28
MX2010007902A (en) 2010-11-25
ES2361459A8 (en) 2011-07-21
CL2008000156A1 (en) 2008-08-01
ES2361459A1 (en) 2011-06-17
CN101977589A (en) 2011-02-16
ES2361459B1 (en) 2012-04-24
PE20091363A1 (en) 2009-10-15
ECSP10010352A (en) 2010-11-30
CA2712527A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
CN101977589B (en) Chitosan gel for dermatological use, production method therefor and use of same
Pires et al. Polymer-based biomaterials for pharmaceutical and biomedical applications: A focus on topical drug administration
Ullah et al. Applications of bacterial cellulose in food, cosmetics and drug delivery
US11191274B2 (en) Biofilm penetrating compositions and methods
AU639163B2 (en) Methyl pyrrolidinone chitosan, production process and uses thereof
EP3060266B1 (en) Chitosan paste wound dressing
KR102659079B1 (en) Chitosan-containing preparations and methods for their preparation and use
WO2014147638A1 (en) A multifunctional natural wound healing matrix
KR20060048401A (en) Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound
Kumar et al. Recent advances in the use of algal polysaccharides for skin wound healing
Kumar et al. Marine-derived polysaccharides and their therapeutic potential in wound healing application-A review
CN108158995A (en) A kind of gynaecology's anti-bacteria foaming agent containing chitosan and preparation method thereof
Gokarneshan Application of natural polymers and herbal extracts in wound management
Kolipaka et al. Stimuli-responsive polysaccharide-based smart hydrogels for diabetic wound healing: Design aspects, preparation methods and regulatory perspectives
Priya et al. Exploring polysaccharide-based bio-adhesive topical film as a potential platform for wound dressing application: A review
Joshi et al. Marine polysaccharides: biomedical and tissue engineering applications
Zubair et al. Emerging trends and challenges in polysaccharide derived materials for wound care applications: A review
JP2010533154A (en) Chitosan carboxyalkylamide hydrogel, its preparation and its cosmetic and dermatological use
Şenel et al. Application of chitosan based scaffolds for drug delivery and tissue engineering in dentistry
EP3656404A1 (en) Film for topical use for treating skin lesions and method for producing and applying same
KR102503193B1 (en) Hydrogel comprising Mushroom-derived Chitosan or derivatives thereof and Manufacturing Method thereof
US20190247421A1 (en) Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan
WO2015013821A1 (en) Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan
Adetunji et al. Nanochitosan derived from marine annelids
Quadir et al. Bioresorbable polymers for wound healing

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141210

Termination date: 20190121

CF01 Termination of patent right due to non-payment of annual fee